SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention ahead of the REGAL Phase 3 AML trials expected 80th-event update and final results, with traders also parsing its ASH presence as a possible sign of a major announcement. Recent price and options activity has fueled speculation about a data leak, short covering, or a buyout, but none of those explanations is confirmed; some traders remain skeptical and are focused on the delay in the milestone update.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is drawing attention after regulators imposed major penalties over anti-money-laundering and sanctions-compliance failures ahead of its quarterly earnings report. Traders debate whether the charge and reputational fallout will weigh on shares or prove manageable, with some viewing the dip as a buying opportunity.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias global settlement with United Therapeutics ends the patent litigation and preserves YUTREPIA sales for PAH, while the PH-ILD indication is being removed. Traders largely welcome the reduced risk and cite managements plan to fund settlement payments with cash and sales, though others worry about the financial burden and lost market opportunity; short-squeeze speculation is also prominent.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

CEO Ryan Cohens latest disclosed open-market purchase of GameStop shares is driving discussion. Many traders view his continued buying as a bullish signal and speculate about a squeeze, while others question the modest share-price response and flag potential dilution tied to the warrants.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians prolonged share-price slide and upcoming earnings are driving discussion, with traders focused on whether the R2 production ramp and delivery growth can translate into better margins and a path to profitability. Bears cite cash burn, execution concerns, and leadership criticism, while bullish traders see the pullback as an opportunity and expect growth from R2 and autonomy initiatives.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

A procedural pause in the federal cannabis-rescheduling hearing, and debate over whether a GAO report should enter the record, have made Schedule III the dominant catalyst for GTBIF. Traders are split between viewing the delay as temporary and buying the selloff, citing Green Thumbs finances and buybacks, and fearing rescheduling could be derailed.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Anthropics report of discovering a CRISPR-like enzyme system has stirred concern about potential competition and weighed on gene-editing stocks. Traders dispute whether ART poses a real threat, noting that its function and ability to edit genes have not been demonstrated.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention as traders debate its selloff ahead of the highly anticipated GTA VI launch. Bulls view the pullback as an opportunity before release, while skeptics cite launch expectations already priced in and uncertainty around leaks, PC timing, and online monetization.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

Skydances distribution and separate trading of long-dated warrants tied to the Warner Bros. Discovery deal is driving discussion, with investors debating eligibility, warrant valuation, and whether the split should pressure the common shares. Reactions are divided between concern over dilution and the combined companys heavy debt, and optimism about the warrants and its expanded media assets.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths third-quarter earnings beat, raised profit outlook and improved medical-cost ratio have put the stock in focus. Many traders view the results as evidence of a turnaround, while others are frustrated that shares gave back early gains and debate whether cost pressures and the quality of the margin improvement limit the bullish case.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $LLY bought Merida Bio today for $2.85B (more than all of SLS) based on PH1B trial data ... 
 
and Just the SLS Secondary Asset - SLS009 is now at the Suggestion of the FDA in a RANDOMIZED Phase 2B - PIVOTAL Trial for front Line AML-MR patients - that will Readout TOP LINE - Again Piviotal Randomized Data Next Quarter - IN 1 Quarter - we&#39;ll ALL KNOW SLS009 IS GETTING FDA Approval. 
 
all approved based on P1 or P2 trial data ... in the last 2 years. 
Revumenib 
Ziftomenib 
Tarlatamab 
Zanidatamab 
Linvoseltamab 
Zenocutuzumab 
Epcoritamab 
Elranatamab 
Talquetamab 
Glofitamab 
Repotrectinib 
Pirtobrutinib 
Adagrasib 
Mosunetuzumab 
Futibatinib 
Tebentafusp 
Ziftomenib 
Sevabertinib 
Dordaviprone 
Avutometinib 
Defactinib

Jeremy Dworkin

Keith Thompson

Captain

Ulaughing

CMSP

$SLS $RVMD Rvmd Pricing $39,800 per month, $775K per year per patient.  
SLS management estimated a &#39;Minimum&#39; of $300K Rev Y1, ...  
  
do the Math:  
 
Gps is worth $50B to big pharma rhe instant the now truly imminent P3 results are announced  
- this $2.8B equity / short rigged $13 / $14 share Price is going to be $135…and Climbing the instant GPs Phase 3 Results are Announced. 
 
Now is the time to be Loading.

StockTwits Web

Revolution Medicines Inc

5,500% ROI this quarter

Lilly(Eli) & Co

 bought Merida Bio today for $2.85B (more than all of SLS) based on PH1B trial data ... 
 
and Just the SLS Secondary Asset - SLS009 is now at the Suggestion of the FDA in a RANDOMIZED Phase 2B - PIVOTAL Trial for front Line AML-MR patients - that will Readout TOP LINE - Again Piviotal Randomized Data Next Quarter - IN 1 Quarter - we'll ALL KNOW SLS009 IS GETTING FDA Approval. 
 
all approved based on P1 or P2 trial data ... in the last 2 years. 
Revumenib 
Ziftomenib 
Tarlatamab 
Zanidatamab 
Linvoseltamab 
Zenocutuzumab 
Epcoritamab 
Elranatamab 
Talquetamab 
Glofitamab 
Repotrectinib 
Pirtobrutinib 
Adagrasib 
Mosunetuzumab 
Futibatinib 
Tebentafusp 
Ziftomenib 
Sevabertinib 
Dordaviprone 
Avutometinib 
Defactinib